



Contact: Diana Yee
Director, Media Relations
510-428-3120
dyee@mail.cho.org

Dr. Bertram Lubin Named Interim Chief Executive Officer of Children's Hospital & Research Center Oakland

August 5, 2009—Oakland, Calif. — Bertram Lubin, M.D., long-time research director at Children's Hospital & Research Center Oakland, was named today as interim president and chief executive officer of the entire hospital organization. Dr. Lubin replaces Frank Tiedemann, who departed today as president and chief executive officer.

“Dr. Lubin is an outstanding leader at Children's Hospital Oakland and has the full confidence of the Board of Directors and Medical Staff to take us forward,” said Harold Davis, chair of the Board of Directors of Children's Hospital & Research Center Oakland.

Dr. Lubin is the hospital's senior vice president, research, and president and director of medical research for the hospital's research arm, Children's Hospital Oakland Research Institute. He has been at Children's since 1973. As interim CEO, he will direct an organization with more than 2,600 employees including 200 doctors, and an annual budget of more than \$300 million.

“I am honored to lead Children's Hospital & Research Center Oakland,” Dr. Lubin said. “There are important challenges ahead, and I look forward to working closely with the medical staff and the communities we serve to deliver the highest quality pediatric care for all children.”

Tiedemann was president and CEO since early 2005. “The Board wishes to express its gratitude and appreciation for Frank Tiedemann's conscientious dedication and service,” Davis said. “Frank's collaboration and vigorous pursuit of our objectives have been important to the communities we serve in these difficult financial times. The Board is most appreciative of his hard work and devotion to Children's Hospital.”

Dr. Lubin began development of the hospital's Sickle Cell Screening, Counseling and Education Program, the Northern California Comprehensive Sickle Cell Center and the Sibling Donor Cord Blood Program, and has been a driving force and catalyst in the expansion and development of basic and clinical research at Children's. Under his leadership, Children's Hospital Oakland Research Institute now manages a budget of

more than \$50 million, has more than 300 research and support staff and ranks sixth in National Institutes of Health funding to children's hospitals in the nation.

Dr. Lubin is an adjunct professor of pediatrics at the University of California, San Francisco and has served on dozens of professional and governmental commissions and committees, lists more than 150 medical/scientific publications and has written several books and chapters related to hematology.

###

About Children's Hospital & Research Center Oakland

Children's Hospital & Research Center Oakland is Northern California's only freestanding and independent children's hospital. Children's is the leader in many pediatric specialties including neonatology, cardiology, neurosurgery and intensive care. The hospital is a designated Level 1 pediatric trauma center and has the largest pediatric critical care facility in the region. Children's Hospital has 190 licensed beds, 201 hospital-based physicians in 30 specialties, more than 2,611 employees and an operating budget of \$312 million. Children's research arm, Children's Hospital Oakland Research Institute, is internationally renowned in bridging state of the art basic science and clinical research for the treatment and prevention of human disease. With about 300 staff members and an annual budget of approximately \$50 million, CHORI is ranked among the top ten research institutes in National Institutes of Health funding to children's hospitals. CHORI is a leader in translational research, providing cures for diseases, developing new vaccines for infectious diseases and discovering new treatment protocols for previously fatal or debilitating conditions such as cancer, sickle cell disease and thalassemia, diabetes, asthma, HIV/AIDS, pediatric obesity, nutritional deficiencies, birth defects, hemophilia and cystic fibrosis.